February 26, 2019 08:02 AM ESTUpdated 08:13 AM
Financing

Temasek leads $85M round for Chi­nese biotech aim­ing for cheap­er, faster, bet­ter CAR-T ther­a­pies

Natalie Grover

Reporter

The land­mark ap­provals of CAR-T ther­a­pies have been her­ald­ed, but emerg­ing sup­ply chain hur­dles cat­alyzed by the com­plex man­u­fac­tur­ing process for the cel­lu­lar ther­a­pies have …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

Neu­ro­gene's stock falls in post-mar­ket trad­ing af­ter ear­ly da­ta in Rett syn­drome

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times